# Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

> **NCT02149875** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai 6th People's Hospital** · enrollment: 84 (actual)

## Conditions studied

- Acute Cerebral Stroke Within 12 Hours for the First Time

## Interventions

- **DRUG:** Dl-3-n-butylphthalide
- **DRUG:** Cerebrolysin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02149875
- **Lead sponsor:** Shanghai 6th People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149875, "Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02149875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*